In Memory of Professor Daopei Lu, MD
1931-2025
Professor Daopei Lu, a towering figure in Chinese medicine, passed away on April 2, 2025, at the age of 93. A renowned hematologist and academician of the Chinese Academy of Engineering, Professor Lu leaves behind a legacy that transformed the field of hematopoietic stem cell transplantation (HCT) and brought hope to countless patients.
Born in 1931, Lu graduated from Tongji Medical College (now part of Huazhong University of Science and Technology) in 1955 and launched his illustrious career at Peking University People’s Hospital. Over the decades, he held prominent roles, including Vice President of the Chinese Medical Association, Director of the Peking University Institute of Hematology, and Chair of the Hematology Branch of the Chinese Medical Association.
A true pioneer, Professor Lu performed Asia’s first bone marrow transplant in 1964—a syngeneic transplant from an identical twin. It was the fourth transplant in the world and the longest-surviving case globally (more than 60 years). Over the decades, he led numerous groundbreaking advancements in stem cell transplantation in China, including:
- China’s first allogeneic bone marrow transplant (1981)
- The first unrelated donor transplant (1992)
- The first ABO-incompatible transplant
- The first haploidentical stem cell transplant (1991)
- The first double-unit umbilical cord blood transplant in an overweight adult (2000)
In the early 2000s, he led the development of the GIAC protocol, achieving world-class results in HLA-haploidentical transplantation, with survival outcomes comparable to matched sibling transplants. This work was published in Blood in 2006.
His innovations extended beyond transplantation. Lu pioneered the use of oral arsenic sulfide (tetra-arsenic tetra-sulfate) for acute promyelocytic leukemia with excellent results, which were published in Blood in 2002. He also explored using garlic extracts as IV infusions to treat cytomegalovirus infection and championed placental gamma globulin as a treatment for GVHD. Under his leadership, China’s five-year HCT survival rates reached world-class levels.
A visionary founder, his other achievements included organizing the China BMT Registry, founding the China Marrow Donor Program (1992), and establishing the first cord blood bank in China (1996). In 1992, he authored “Leukemia Therapeutics,” China’s first comprehensive textbook on leukemia treatment.
Lu established the Peking University Institute of Hematology in 1981, Beijing Daopei Hospital in 2001, the China Hematopoietic Stem Cell Transplantation Cooperative Group, and the Lu Daopei Medical Group, for which he served as Medical Director. 
Lu’s extraordinary achievements earned him a host of accolades, including the State Science and Technology Progress Award (1985), Chinese Medical Association Technology Progress Award (2006), Beijing Science and Technology Progress Award (2006), the Ho Leung Ho Lee Foundation Science and Technology Progress Award (1997), the Chen Jiageng Science Award (1997), and the Lifetime Achievement Award from both the Chinese Anti-Cancer Association Hematologic Oncology (2016) and the Chinese Hematology Association (2020). In 2016, the Center for International Blood and Marrow Transplant Research (CIBMTR) honored him with the Distinguished Service Award.
Beyond his scientific prowess, Lu was a dedicated mentor, shaping generations of medical talent—academicians, PhDs, and postdoctoral researchers—who carry forward his commitment to excellence. His relentless pursuit of innovation and compassionate care touched countless lives, cementing his place as a giant in Chinese hematology.
Moreover, he was a true gourmet with a deep passion for food. He enjoyed singing in both English and Chinese, including Peking Opera. A man of many talents, he also played the violin and excelled in calligraphy, wielding the brush with remarkable mastery.
Professor Lu Daopei’s passing is a profound loss, but his spirit endures in the lives he saved, the minds he inspired, and the advancements he pioneered. His legacy will continue to light the way for future generations of physicians and scientists striving to push the boundaries of medicine. We mourn his loss with heavy hearts and honor his memory with the deepest respect.
Perspectives:
Retreat, Reset, Rejuvenate, and Adapt …
By Sumithira Vasu, MBBS, MD
Every February, hundreds of physicians, nurses, advanced practice providers, and other members of the transplant and cell therapy research and care delivery community gather at the Tandem Meetings of ASTCT and CIBMTR to learn and reconnect. This year, set in the picturesque almost-paradise of Hawaii, the meetings offered plenty of opportunities to learn, be challenged, connect, reconnect, and adapt. Sessions featuring speakers from industry and global gene therapy initiatives broadened the usual focus on individual research or clinical practice, leaving me with plenty of food for thought.
We constantly innovate as we adapt to many advances in GVHD and new life-saving cellular therapies across an ever-expanding range of indications. We have a strong international community that shares our passion and desire for excellence. Hence the meetings offer a prime opportunity not only to learn but also to connect with current collaborators, forge new partnerships, and seek sage counsel from trusted mentors from all over the world.
If you are within 5 years of entry into the cell therapy and transplant field, actively seek out how you can contribute and avail yourself of the opportunities in the transplant community. If you are interested in CIBMTR and how registries work, then consider applying to the Page Scholars Program which offers early career investigators a peek into CIBMTR Working Committee research efforts over a two-year period. If you want to drive system-wide change and see an opportunity in clinical care delivery, explore the various opportunities within CIBMTR or ASTCT. Consider participating in the many ASTCT Special Interest Groups and / or CIBMTR Working Committees.
Over the last few weeks, I have attended many meetings filled with anxiety about what the future brings. Some attendees have faced disruption of routines that determine research funding, while others are recalibrating what they want to study or feeling completely helpless. The Tandem Meetings reminded me of the endurance and resilience of the members in this field. I particularly enjoyed Dr. Sergio Giralt’s words when conferred the CIBMTR Distinguished Service Award.- The arc of his life, and how he turned seeming setbacks into paradigm-shifting insights because of his North Star in service, and scientific contribution through collaboration, was inspiring.
While we are all skilled at compartmentalization, the last few months have tested those skills. I want to share insights from a book titled “Four Questions”1 by Vaisesika Dasa. The author argues that questions help us find our way even in daily situations, particularly in rapidly changing and stressful situations. The four questions are:
- What is my purpose?
- What is the lesson?
- How can I be of service?
- Where should I be investing my time and attention right now?
Asking these questions in various aspects of work and life, in general, has helped me clarify goals and stay productive.
Despite all the anxieties we may have, one only needs to walk into the clinic to meet an anxious patient awaiting their first BMT consult to put things into perspective. After discussing the challenges of an allo transplant and often instigating tears, witnessing these patients enroll in trials, give their best while facing uncertainty every day, and eventually return to productive lives fills me with optimism and resilience. It reminds me to focus on only the things that I can control.
Makapuʻu Point Lighthouse Trail, Oahu, HI
When I leave the Tandem Meetings, I always come back with a renewed sense of purpose, enthusiasm, and determination. So, no matter what the future holds, I have decided to squarely focus on what I can do. I have several meetings in the next two weeks exploring new collaborations with people that I met at the Tandem Meetings. I am eternally grateful for this community that lives by Friedrich Nietzsche’s philosophy “That which does not kill us makes us stronger.”
References
- Vaiseseika dasa. The Four Questions: A Pathway to Inner Peace. Bhaktivedanta Book Trust ; 2024.
Infection and Immune Reconstitution Working Committee
Pictured left to right: Christen Ebens, Joshua Hill, Jeff Auletta (Interim Scientific Director), Anna Huppler, Hemant Murthy, Chris Dandoy (Outgoing Co-Chair), Michael Martens, and Qiran (Lexie) Ye.
Committee Leadership
Co-Chairs:
- Joshua Hill, Fred Hutchinson Cancer Center, Seattle, WA
- Hemant Murthy, Mayo Clinic Florida, Jacksonville, FL
- Christen Ebens, University of Minnesota, Minneapolis, MN
Scientific Director:
- Anna Huppler, CIBMTR MCW, Milwaukee, WI
Statistical Director:
- Michael Martens, CIBMTR MCW, Milwaukee, WI
Statistician:
- Qiran (Lexie) Ye, CIBMTR MCW, Milwaukee, WI
CIBMTR Page Scholar:
- Zeinab El Boghdadly, Ohio State University, Columbus, OH
Infection and a requirement for immune reconstitution are consequences of transplant and non-transplant cellular therapies. The risks of infection and rates of immune reconstitution have shifted with changes in conditioning regimens, advances in GVHD prophylaxis, innovations in non-transplant cellular therapy, and expanding indications for all cellular therapy. The Infection and Immune Reconstitution Working Committee provides scientific oversight for studies of the epidemiology, prevention, and treatment of post-transplant and cellular therapy infections and issues related to the recovery of immune function. Our studies provide evidence to guide changes in supportive care guidelines and risk assessments for a rapidly advancing field. Completed and in-progress studies over the last few years focused on the infectious risks of post-transplant cyclophosphamide and CAR-T cell therapy as well as the impact of emerging therapeutics and infections.
After two decades of leading the Infection and Immune Reconstitution Working Committee, Marcie Riches, MD, stepped down from the scientific director position in 2024. The committee greatly misses her expertise and experience but is committed to continuing her legacy of guiding high-quality and timely studies of infection and immune function after cellular therapy.
Zeinab El Boghdadly, MBBCh, from The Ohio State University, is in her second year serving on the committee as our Page Scholar. She actively contributes to our committee activities, including Tandem Meetings working committee proposal reviews, manuscript preparation, and data form optimization. She will soon begin working on her accepted combined / collaborative proposal.
Our accomplishments in the last 2 years include publishing 2 high-impact manuscripts in journals in our field. The study results included:
- Demonstration of higher incidence of bacterial infections in patients receiving post-transplant cyclophosphamide-based GVHD prophylaxis compared to calcineurin inhibitor-based prophylaxis (Bone Marrow Transplantation)
- Evaluation of fungal infection rates and outcomes in patients receiving post-transplant cyclophosphamide or calcineurin inhibitor-based GVHD prophylaxis (Transplantation and Cellular Therapy)
The committee is working on 7 projects, and we anticipate publishing 3 manuscripts in 2025. You can view planned, in-progress, and completed studies and publications on CIBMTR’s Infection and Immune Reconstitution Working Committee webpage. We welcome participation from the infectious diseases, immunology, and transplantation and cellular therapy communities throughout the lifecycle of each project. Our success depends on your new ideas and openness to collaborations with others in the field. Please also reach out to the working committee chairs or scientific director when preparing a proposal for the Infection and Immune Reconstitution Working Committee. Committee leadership actively works to find creative ways to leverage the strengths of CIBMTR’s database and statistical expertise to answer pressing questions related to infection and immune reconstitution. We look forward to robust representation and fruitful discussion at the 2026 Tandem Meetings in Salt Lake City, UT, next February.
Lymphoma Working Committee
Pictured left to right: Kwang Woo Ahn, Peter Riedell, Mehdi Hamadani, Mazyar Shadman, Alex Herrera, and Jinalben Patel.
Committee Leadership
Co-Chairs:
- Alex Herrera, City of Hope, Duarte, CA
- Peter Riedell, University of Chicago, Chicago, IL
- Mazyar Shadman, Fred Hutchinson Cancer Center, Seattle, WA
Scientific Director:
- Mehdi Hamadani, CIBMTR MCW, Milwaukee, WI
Statistical Director:
- Kwang Woo Ahn, CIBMTR MCW, Milwaukee, WI
Statistician:
- Jinalben Patel, CIBMTR MCW, Milwaukee, WI
The Lymphoma Working Committee, one of the first committees CIBMTR established, focuses on HCT and cellular therapy for both Hodgkin and non-Hodgkin lymphomas. The committee has conducted numerous studies addressing a wide range of issues related to these diseases. Since November 2023, when the committee last published in this newsletter, the committee published 5 peer-reviewed manuscripts in Blood Advances, Haematologica, Blood Cancer Journal, British Journal of Haematology, and Leukemia. The Lymphoma Working Committee actively contributed to presentations in 2024 and early 2025, delivering 4 poster abstracts at Tandem Meetings. Additionally, the Working Committee helped create guidelines for using HCT and cellular therapy to treat mantle cell lymphoma and diffuse large B-cell lymphoma.
The increasing adoption of CD19-directed CAR-T therapy in non-Hodgkin lymphomas, including large B-cell lymphoma (LBCL), follicular lymphoma, and mantle cell lymphoma, has fostered robust clinical investigation. The committee has worked to address key questions in the lymphoma field, including those concerning the evolving role of cellular therapy and HCT in LBCL. Lymphoma Working Committee analyses have provided insights into the application of CAR-T therapy for LBCL in complete remission with additional studies examining the role of CAR-T versus HCT in patients with LBCL in complete remission. Updates in the lymphoma disease-specific forms have facilitated nuanced analyses, including studies evaluating the role of CAR-T therapy in select subgroups, such as those with T-cell / histiocyte-rich LBCL along with secondary central nervous system lymphoma. These CIBMTR analyses helped shape clinical practice by providing real-world evidence of HCT and cellular therapy outcomes.
With CIBMTR’s robust research database, the Lymphoma Working Committee is uniquely equipped to address knowledge gaps in the field and inform clinical practice in various transplant- and cellular therapy-related matters.
The Lymphoma Working Committee continues to remain extremely active, leveraging the extensive data available in CIBMTR’s Outcomes Database. The table below lists the number of lymphoma transplants that were added to the outcomes database from 2008 through 2024. During the annual committee meeting at the 2025 Tandem Meetings, presenters shared 6 new proposals. More than 135 people attended the Lymphoma Working Committee meeting, and the great involvement from the transplant community helps the committee continue to produce timely and substantive research.
2025 Tandem Meetings I Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR
By Alicia Halfmann and Maira Brey
We are thrilled to announce that a total of 5,366 attendees from 58 countries joined us in-person (76%) and digitally (24%) for the 2025 Tandem Meetings, held at the Hawaiʻi Convention Center in Honolulu, HI.
Program Co-Chairs, Marie Bleakley, MD, PhD, MMsc, and Melody Smith, MD, MS, along with the Scientific Organizing Committee, put together an excellent educational program. The meetings also included the following educational content:
- 6 Plenary Sessions
- 9 Concurrent Sessions
- 8 Satellite Symposia Sessions
- 16 Oral Abstract Sessions
- 11 Product and Innovation Theaters
- 11 CIBMTR Working Committee Meetings
- 9 ASTCT Spotlight Sessions
- 12 Meet-the-Professor Sessions
- 9 Educational Tracks
- 657 Posters with a Meet-the-Authors Reception
Awards
2025 CIBMTR Distinguished Service Award recipient: Fernando Barroso Duarte, PhD
2025 ASTCT Lifetime Achievement Award recipient: Joseph Antin, MD
Lectures
Mortimer M. Bortin Lecture: Sergio Giralt, MD: Something Funny Happened On My Way to Tandem
Click here for more information.
E. Donnall Thomas Lecture: Robert Zeiser, MD: Immune Mediated Side Effects and Cancer Immune Escape After Immunotherapy
Click here for more information.
Networking
The meetings offered several networking opportunities, including the Tandem Meetings Welcome Reception, the Poster Reception: Meet the Authors, and the Tandem Meetings Closing Reception.
Session Recording Access:
Registered attendees can access session recordings from the 2025 Tandem Meetings via the Recording Index page of the online program. You must log into the site to access the recordings. Your login information is your registrant ID (found on your registration confirmation email) and your last name.
If you did not attend the 2025 Tandem Meetings and want to purchase access to the recorded content, visit the Session Recording Access page to view rates and instructions.
Thank you!
On behalf of the Tandem Meetings of ASTCT & CIBMTR Planning Team, we thank you for all your time, hard work, and dedication to the field; these meetings would not be successful without all of you.
We look forward to seeing you at the Salt Palace Convention Center in Salt Lake City, UT, February 4-7, with pre-conference on February 3, 2026!
Watch for details of the 2026 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR in the coming months. Contact TandemMeetings@mcw.edu for information regarding support opportunities for next year’s meetings.
Join the conversation: #Tandem26
2025 Tandem Meetings: Clinical Research Professionals / Data Management Track
By Jillian Kissinger
CIBMTR Data Operations staff during the 2025 Clinical Research Professionals / Data Management Track
We had a highly successful Clinical Research Professionals / Data Management Track at the 2025 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR in beautiful Honolulu, HI. More than 200 people attended our in-person sessions on February 11-12. This year we also had more than 350 unique viewers for our Digital Access option, which allowed those attendees to view the recordings online within 3 hours of the sessions.
Presentation highlights included various “Form Spotlights” on CLL, thalassemia and sickle cell disease, solid tumors, and our TED forms. Our “Data Operations: Past, Present, and Future” session provided information, including our annual CIBMTR overview as well as interesting facts about Data Operations past, functional highlights from 2024, and our goals and vision for the future. Sessions also included presentations on subsequent primary neoplasms after cellular therapies, the annual Center-Specific Survival Analysis, frequently asked questions and case studies; breakout sessions for US and international centers; and functional area updates from Data Capture, Audit, FormsNet3, and Data Automation teams. We heard from NMDP’s Implementation Science team about the important work they are doing with your data, and we had a session with CIBMTR’s PRO Protocol team discussing barriers and facilitators to enrolling patients.
Our new “Center Idea Sharing” sessions included engaging conversations amongst data professionals to discuss staffing and efficiencies at large centers and small centers as well as methods to build more physician engagement. We had several data professionals present their unique perspectives and ideas from their centers: Nikkole Valdez from UCI Health, Chandan Kumar Harikrishna from BC Children’s Hospital, and Laurin Cummins and Tyler Heflin from SSM Health Saint Louis University Hospital.
Hector Zambrano from Sarah Cannon Transplant and Cellular Therapy Network received this year's award for best oral abstract for his presentation titled, “Data management adjusted productivity model within the Sarah Cannon Transplant and Cellular Therapy Network (SCTCTN)- Process and benefits.”
Best oral abstract recipient, Hector Zambrano, poses for a photo with Eileen Tuschl, Director of CIBMTR MCW Data Operations.
Additional oral abstracts included:
- “Standardization of provider notes for accuracy in data reporting” presented by Jennifer Polo from Penn Medicine
- “Data management GVHD auditing tool to reduce reporting errors” presented by Julie Parker from Baylor University Medical Center
You can access the presentation slides from the 2025 Clinical Research Professionals / Data Management Track on the CIBMTR Portal > Training & eLearning Tile > Tandem Meetings CRP/ DM Track. We will post the recording files here in the coming months.
A special thank you to all who completed the evaluations! We use this feedback to improve our track and make it as meaningful and impactful as possible. We look forward to seeing you next year in Salt Lake City, UT, for more collaboration, idea sharing among centers, and the latest and greatest information from CIBMTR Data Operations.
Peptide Binding Motif (PBM) Matching of HLA Class I Alleles Online Tool
An updated version of the online web tool for PBM matching of HLA class I alleles is now available at https://pbm-matching-tool.b12x.org/!
Figure 1: Screenshot of the PBM tool available at https://pbm-matching-tool.b12x.org/.
Mismatched HLA class I molecules present a large repertoire of peptides (immunopeptidomes), which can be potential targets of T-cell alloreactivity after allogeneic HCT. Therefore, the degree of immunopeptidome divergence between patient and donor HLA can affect clinical outcomes. Researchers can predict immunopeptidome divergence between HLA class I allele mismatches by classifying HLA molecules into different groups based on PBM defined by publicly available immunopeptidome datasets. In accordance with associated transplant outcomes analysis patterns, researchers predict that in HCT performed under conventional, non-post-transplant cyclophosphamide-based immune prophylaxis, HLA class I mismatches across PBM groups in the graft-versus-host (GVH) vector (unidirectional GVH or bidirectional) will be less well tolerated than mismatches within the same PBM group or in the host-versus-graft (HVG) vector (PBM matched or unidirectional HVG)1,2.
In conjunction with the CIBMTR Immunobiology Working Committee study1 for which these analyses were conducted, we developed an online PBM calculator to facilitate classification of the PBM matching status of patient and candidate donors based on high-resolution HLA typing data. Since the tool’s launch in 2023, 1,357 visitors from 52 countries around the globe accessed the online PBM calculator.
Figure 2: Global overview of HLA class I PBM matching tool users. This map shows the number of users per country in different shades of blue, and the table bedside it lists the seven countries with the highest user counts.
Version 1 of the online web tool included 122 HLA class I alleles in 21 PBM groups. This covers 95/203 (47%) common alleles in worldwide populations (61% in Europeans)1. Researchers have made more immunopeptidomics data for HLA class I alleles available since the completion of that study. Using the new data, researchers introduced the following updates in version 2 of the online web tool:
- 28 additional alleles received PBM assignments, for a total of 150 alleles
- 2 additional PBM groups were identified, for a total of 23 PBM groups
- 18 alleles were moved from one PBM group to another
- 2,338 alleles with identical peptide-binding domains (P-groups) were assigned to the relevant PBM groups
Version 2, therefore, includes a total of 2,488 HLA class I alleles. This covers 121/203 (60%) common alleles in worldwide populations (75% in Europeans), according to the Common and Well-Documented catalog. The EBMT study2 validated it, demonstrating its informativeness in 85% of MMUD pairs.
CIBMTR researchers are currently developing PBM groups for HLA class II alleles. Stay tuned!
References
1Crivello P, Arrieta-Bolaños E, He M, Wang T, Fingerson S, Gadalla SM, Paczesny S, Marsh SGE, Lee SJ, Spellman SR, Bolon YT, Fleischhauer K. Impact of the HLA Immunopeptidome on Survival of Leukemia Patients After Unrelated Donor Transplantation. J Clin Oncol 2023 May 1;41(13):2416-2427. doi: 10.1200/JCO.22.01229. PMID: 36669145.
2Arrieta-Bolaños E, Bonneville EF, Crivello P, Robin M, Gedde-Dahl T, Salmenniemi U, Kröger N, Yakoub-Agha I, Crawley C, Choi G, Broers AEC, Forcade E, Carre M, Poiré X, Huynh A, Reményi P, Lenhoff S, Ciceri F, Tholouli E, Schroeder T, Deconinck E, Carlson K, de Wreed LC, Hoogenboom JD, Malard F, Ruggeri A, Fleischhauer K. HLA Mismatching and Survival in Contemporary Hematopoietic Cell Transplantation for Hematological Malignancies. J Clin Oncol 2024 Oct;42(28):3287-3299. doi: 10.1200/JCO.24.00582. PMID: 39167735.
Stephanie Fingerson, Yung-Tsi Bolon (CIBMTR, Minneapolis, USA)
Pietro Crivello, Katharina Fleischhauer (University Hospital Essen, Germany)
SCTOD: Center-Specific Survival Analysis and Center Outcomes Forum
By Carol Doleysh
The SCTOD is part of the US HRSA-funded C.W. Bill Young Cell Transplantation Program that collects data on all allogeneic HCT performed in the US and on transplants done elsewhere using cellular products that originated in the US.
Outcomes reporting in allogeneic HCT is necessary to provide information that patients, payers, and government agencies request and to comply with current laws. The SCTOD contract requires CIBMTR to conduct an analysis of one-year survival rates at each US transplant center annually. CIBMTR generates the report to serve as a quality improvement tool for transplant centers. The analysis includes only transplant centers that maintain at least one year of follow-up on more than 90% of related and unrelated HCT recipients within the reporting period.
In mid-December, CIBMTR distributed the 2024 Center-Specific Survival Analysis (CSA) Report, which includes first allogeneic HCT performed in the US between 2020 and 2022, to center directors, payers, and FACT. CIBMTR provided an Executive Summary for the first time this year, highlighting key elements of the report and analysis results. CIBMTR updated the data on both the NMDP website and quality improvement tools for transplant centers (Center Performance Analytics and the Survival Calculator, available via the secure CIBMTR Portal). Submit any questions regarding CIBMTR Portal account credentials via CIBMTR Center Support (https://nmdp.service-now.com/csm) by selecting CIBMTR Center Maintenance then CIBMTR Portal Help.
Attendees at the 2023 Center Outcomes Forum recommended holding an informational session during the Tandem Meetings to provide key updates about the CSA, including updated risk adjustment, analysis findings, and future plans. The session offered important stakeholder groups, especially center medical directors, administrative directors, and data professionals, the opportunity to learn more about the CSA firsthand. The dedicated CSA page (https://cibmtr.org/CIBMTR/Resources/Center-Specific-Survival-Analysis) contains a link to this webinar (https://vimeo.com/1063260712), along with information on CSA methodology, frequently asked questions, Center Outcomes Forums, and links to the CIBMTR Portal and NMDP Transplant Center Directory.
Because CIBMTR is committed to continuously improving this high-impact report, the team is planning the next Center Outcomes Forum for Fall 2025. This meeting is a venue to discuss CIBMTR’s approach to the Center-Specific Survival Analysis and provide meaningful recommendations for improvement. CIBMTR is determining topics for the 2025 Forum and will extend invitations based on those topics. Invitees will include representatives of the HCT community, such as transplant physicians and center directors, the ASTCT and its Committee on Quality Outcomes, FACT, governmental funding agencies, patients, private payors, and statisticians. You can find details of all previous Center Outcomes Forums, including agendas and summaries, on the CIBMTR website (https://cibmtr.org/CIBMTR/Meetings/Materials-Archive/Center-Outcomes-Forum).
Our Supporters
CIBMTR is supported primarily by Public Health Service U24CA076518 from the National Cancer Institute (NCI), the National Heart, Lung and Blood Institute (NHLBI), and the National Institute of Allergy and Infectious Diseases (NIAID); U24HL138660 from NHLBI and NCI; 75R60222C00008, 75R60222C00009, and 75R60222C00011 from the Health Resources and Services Administration (HRSA); and N00014-24-1-2057 and N00014-25-1-2146 from the Office of Naval Research.
Additional federal support is provided by OT3HL147741, P01CA111412, R01CA100019, R01CA218285, R01CA231838, R01CA262899, R01AI128775, R01AI150999, R01AI158861, R21AG077024, U01AI069197, U01AI184132, U24HL157560, andUG1HL174426.
Support is also provided by Boston Children’s Hospital; Fred Hutchinson Cancer Center; Gateway for Cancer Research, Inc.; Jeff Gordon Children’s Foundation; Medical College of Wisconsin; NMDP; Patient Center Outcomes Research Institute; PBMTF; St. Baldricks’s Foundation; Stanford University; Stichting European Myeloma Network (EMN); and from the following commercial entities: AbbVie; Actinium Pharmaceuticals, Inc.; Adaptimmune LLC; Adaptive Biotechnologies Corporation; ADC Therapeutics; Adienne SA; Alexion; AlloVir, Inc.; Amgen, Inc.; Astellas Pharma US; AstraZeneca; Atara Biotherapeutics; Autolus Limited; BeiGene; BioLineRX; Blue Spark Technologies; bluebird bio, inc.; Blueprint Medicines; Bristol Myers Squibb Co.; CareDx Inc.; Caribou Biosciences, Inc.; CSL Behring; CytoSen Therapeutics, Inc.; DKMS; Editas Medicine; Elevance Health; Eurofins Viracor, DBA Eurofins Transplant Diagnostics; Gamida-Cell, Ltd.; Gift of Life Biologics; Gift of Life Marrow Registry; HistoGenetics; In8bio, Inc.; Incyte Corporation; Iovance; Janssen Research & Development, LLC; Janssen/Johnson & Johnson; Jasper Therapeutics; Jazz Pharmaceuticals, Inc.; Karius; Kashi Clinical Laboratories; Kiadis Pharma; Kite, a Gilead Company; Kyowa Kirin; Labcorp; Legend Biotech; Mallinckrodt Pharmaceuticals; Med Learning Group; Medac GmbH; Merck & Co.; Mesoblast, Inc.; Millennium, the Takeda Oncology Co.; Miller Pharmacal Group, Inc.; Miltenyi Biotec, Inc.; MorphoSys; MSA-EDITLife; Neovii Pharmaceuticals AG; Novartis Pharmaceuticals Corporation; Omeros Corporation; Orca Biosystems, Inc.; OriGen BioMedical; Ossium Health, Inc.; Pfizer, Inc.; Pharmacyclics, LLC, An AbbVie Company; Registry Partners; Rigel Pharmaceuticals; Sanofi; Sarah Cannon; Seagen Inc.; Sobi, Inc.; Sociedade Brasileira de Terapia Celular e Transplante de Medula Óssea (SBTMO); Stemcell Technologies; Stemline Technologies; STEMSOFT; Takeda Pharmaceuticals; Talaris Therapeutics; Vertex Pharmaceuticals; Vor Biopharma Inc.; Xenikos BV.